Acumen Pharmaceuticals, Inc. (ABOS) Social Stream
Acumen Pharmaceuticals Inc (ABOS) Price Targets From Analysts
Use the tables below to see what analysts covering Acumen Pharmaceuticals Inc think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
Over the past 29 weeks, ABOS's average upside potential has been 136.08%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
ABOS Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
ABOS's average broker recommendation rating improved by 0.67 over the prior 120 days.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ABOS as an investment opportunity.
- ABOS has a higher upside potential (average analyst target price relative to current price) than 383.23% of all US stocks.
- Acumen Pharmaceuticals Inc's number of analysts covering the stock is higher than 44.56% of all US stocks.
- In terms of how Acumen Pharmaceuticals Inc fares relative to stocks in the small market cap category, note that its variance in analysts' estimates is lower than -159.02% of that group.
- To contextualize these metrics, consider that out of Healthcare stocks, Acumen Pharmaceuticals Inc's average analyst price target is higher than 146.56% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Acumen Pharmaceuticals Inc are MTEX, MNMD, and CDXC.
Make investment decisions regarding ABOS using the data that counts. Try POWR Ratings for free.